Clinical - ABL SA : ABL SA

Read more

EMRs - Registries - Integration tool

Read more

Clinical solutions

Discover our solutions

Clinical applications

Discover our applications

ABL Announces Distribution Agreement with ELTA 90 Medical Science in Serbia & Montenegro

Nov 30, 2018

Advanced Biological Laboratories (ABL) S.A. and ELTA 90 Medical Science are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Serbia and Montenegro. See current channel partners.
Read more
New poster on HIV resistance to be presented at the HIV DART 2018 congress

Oct 29, 2018

We are pleased to announce that a new poster communication entitled “Clinical resistance to dolutegravir assessed by next-generation sequencing in patients pre-exposed to raltegravir” will be presented at the HIV DART and Emerging Viruses 2018 congress in Miami (USA, 27-29 November 2018)…
ABL Announces Distribution Agreement with Bio-Active Co., Ltd. in Thailand

Oct 25, 2018

Advanced Biological Laboratories (ABL) S.A. and Bio-Active Co., Ltd. are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Thailand. See current channel partners.
Read more

DeepChek® Assays Fully Validated on the Applied Biosystems SeqStudio Genetic Analyzer

Oct 23, 2018

ABL is pleased to announce the validation of its DeepChek® Line of Assays on the Applied Biosystems SeqStudio Genetic Analyzer. Download the technical note for more information.
Read more
ABL Welcomes you at MEDICA 2018

Oct 22, 2018

ABL will be attending the next MEDICA forum in Dusseldorf from 12 – 15 November 2018: Hall 3 / B70 Our team will provide information on our portfolio: Laboratories, virologists and microbiologists: DeepChek® Assays (Genotyping & Drug Resistance) UltraGene® Assays (Viral Load Detection) Dee…
Read more
DeepChek®-HIV RT/PROT and DeepChek®-HIV INT Genotyping Assays Successfully Passed 2017 National Quality Control Program with 100% Accuracy.

Oct 15, 2018

We are pleased to announce that, after 2015 and 2016, the DeepChek®-HIV RT/PROT assay and the DeepChek®-HIV INT assay successfully passed a national quality control program in France, Switzerland and emerging countries (ANRS CQ 2017) through an independent lab and obtained 100% positive results on s…
Read more

DeepChek® Assays Fully Validated on the Illumina iSeq 100 Sequencing System

Oct 10, 2018

ABL is pleased to announce the validation of its DeepChek® Line of Assays on the Illumina iSeq 100 Sequencing System. Download the technical note for more information.
Read more
Immediate Availability of a New DeepChek Assay for Herpes Simplex Virus (HSV) Genotyping and Drug Resistance

Oct 01, 2018

ABL is pleased to announce the immediate availability of a new DeepChek® Assay intended to be used for Herpes Simplex Virus (HSV) genotyping and for determining the presence of mutations within UL23 (thymidine kinase) and UL30 (DNA polymerase) conferring drug resistance to antiviral drugs – DE…
Read more
Renewal of ISO 9001 certification for CDL Pharma

Sep 27, 2018

CDL Pharma, an ABL Group’s affiliate, obtained the renewal of conformity certification of its Quality System, in compliance with the standard UNI EN ISO 9001:2015. We focus to provide our customers high quality products and services which satisfy all requirements from applicable regulations an…
Read more